Back to market news

Publisher feeds · checked hourly

F.D.A. Rejects Closely Watched Lung Cancer Drug From China

Source excerpt

The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.

Read the original story

This page contains a short source excerpt and linked metadata, not a republication of the complete article. The original publisher retains its content.

Explore this story

Keywords come from the source feed. Topics use literal text matches; tickers, listing markets and sentiment appear only when supplied. These labels are navigation aids, not independently verified classifications.

Headlines and short introductions belong to the identified publishers. Full stories open on their original sites and may require a subscription. For informational and educational purposes.